The clinical phase of AD is marked by selective neuronal death, synaptic loss, and neurotransmitter loss (Holtzman et al., 2011), mainly because of genetic variance such as those of APOE and TAU (Ma et al., 1994; Petersen et al., 1995; Johnson and Jenkins, 1999; Ballatore et al., 2007). Here, APOE is linked to Alzheimer disease.